Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics...